{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:27:02Z","timestamp":1791599222773,"version":"4.3.4"},"reference-count":209,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002848","name":"Comisi\u00f3n Nacional de Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["2001050151"],"award-info":[{"award-number":["2001050151"]}],"id":[{"id":"10.13039\/501100002848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002848","name":"Comisi\u00f3n Nacional de Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["2101050160"],"award-info":[{"award-number":["2101050160"]}],"id":[{"id":"10.13039\/501100002848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002848","name":"Comisi\u00f3n Nacional de Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PIA\/APOYO CCTE AFB170007"],"award-info":[{"award-number":["PIA\/APOYO CCTE AFB170007"]}],"id":[{"id":"10.13039\/501100002848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016714","name":"University of Sharjah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016714","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005642","name":"Universit\u00e0 degli Studi di Sassari","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005642","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["451-03-68\/2022-14\/200378"],"award-info":[{"award-number":["451-03-68\/2022-14\/200378"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["451-03-68\/2022-14\/200116"],"award-info":[{"award-number":["451-03-68\/2022-14\/200116"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ejmech.2022.114217","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T11:12:20Z","timestamp":1646219540000},"page":"114217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["Natural products and synthetic analogues against HIV: A perspective to develop new potential anti-HIV drugs"],"prefix":"10.1016","volume":"233","author":[{"given":"Jelena","family":"Popovi\u0107-Djordjevi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Quispe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Giordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Kosti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena S.","family":"Katani\u0107 Stankovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Valere","family":"Tsouh Fokou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Martorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Pintus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7301-8151","authenticated-orcid":false,"given":"Javad","family":"Sharifi-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca Oana","family":"Docea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Calina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114217_bib1","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3201\/eid2706.210284","article-title":"Reflections on 40 Years of AIDS","volume":"27","author":"De Cock","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ejmech.2022.114217_bib2","series-title":"Acquired Immune Deficiency Syndrome (AIDS)","author":"Waymack","year":"2019"},{"key":"10.1016\/j.ejmech.2022.114217_bib3","series-title":"Global HIV & AIDS Statistics \u2014 Fact Sheet","author":"Unaids","year":"2021"},{"key":"10.1016\/j.ejmech.2022.114217_bib4","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/molecules20010648","article-title":"Lectins with anti-HIV activity: a review","volume":"20","author":"Akkouh","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.114217_bib6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(06)69157-5","article-title":"HIV\/AIDS epidemiology, pathogenesis, prevention, and treatment","volume":"368","author":"Simon","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114217_bib7","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1080\/07391102.2019.1663263","article-title":"Design of metronidazole derivatives and flavonoids as potential non-nucleoside reverse transcriptase inhibitors using combined ligand- and structure-based approaches","volume":"38","author":"Cutinho","year":"2020","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2022.114217_bib8","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.virol.2014.02.021","article-title":"HIV cure research: advances and prospects","volume":"454\u2013455","author":"Passaes","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.ejmech.2022.114217_bib9","first-page":"2946730","article-title":"Applications of click chemistry in the development of HIV protease inhibitors","author":"Mudgal","year":"2018","journal-title":"Int. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","article-title":"The development of antiretroviral therapy and its impact on the HIV-1\/AIDS pandemic","volume":"85","author":"Broder","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2022.114217_bib11","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.drudis.2019.03.013","article-title":"New targets for HIV drug discovery","volume":"24","author":"Puhl","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2022.114217_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000331995","article-title":"Targets for inhibition of HIV replication: entry, enzyme action, release and maturation","volume":"55","author":"Sierra-Aragon","year":"2012","journal-title":"Intervirology"},{"key":"10.1016\/j.ejmech.2022.114217_bib13","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bjp.2018.10.006","article-title":"Chemical diversity and activity profiles of HIV-1 reverse transcriptase inhibitors from plants","volume":"29","author":"Chinsembu","year":"2019","journal-title":"Rev. Brasil. de Farmacogn."},{"key":"10.1016\/j.ejmech.2022.114217_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jep.2017.08.005","article-title":"Anti-HIV activity of southern African plants: current developments, phytochemistry and future research","volume":"210","author":"Prinsloo","year":"2018","journal-title":"J.\u00a0Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2022.114217_bib15","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40262-014-0167-9","article-title":"Pharmacokinetic enhancers in HIV therapeutics","volume":"53","author":"Larson","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2022.114217_bib16","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2022.114217_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3389\/fphar.2015.00237","article-title":"Natural products and drug discovery: a survey of stakeholders in industry and academia","volume":"6","author":"Amirkia","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114217_bib18","unstructured":"T. PlantList, in.."},{"key":"10.1016\/j.ejmech.2022.114217_bib19","doi-asserted-by":"crossref","first-page":"112230","DOI":"10.1016\/j.jep.2019.112230","article-title":"Best practice in research \u2013 overcoming common challenges in phytopharmacological research","volume":"246","author":"Heinrich","year":"2020","journal-title":"J.\u00a0Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2022.114217_bib20","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1128\/MMBR.63.4.836-843.1999","article-title":"Retroviral DNA integration","volume":"63","author":"Hindmarsh","year":"1999","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.ejmech.2022.114217_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.674682","article-title":"Bioactive compounds as potential agents for sexually transmitted diseases management: a review to explore molecular mechanisms of action","volume":"12","author":"Sharifi-Rad","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114217_bib22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41586-018-0804-9","article-title":"Structural basis of coreceptor recognition by HIV-1 envelope spike","volume":"565","author":"Shaik","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114217_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.virol.2020.01.017","article-title":"Comparison of the antiviral activity of the microbicide candidate griffithsin and its tandemers derivatives against different modes of HIV-1 transmission","volume":"544","author":"Alexandre","year":"2020","journal-title":"Virology"},{"key":"10.1016\/j.ejmech.2022.114217_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/B978-0-12-387669-0.00020-X","article-title":"Anti-HIV activity of extracts and compounds from marine algae","volume":"64","author":"Kim","year":"2011","journal-title":"Adv. Food Nutr. Res."},{"key":"10.1016\/j.ejmech.2022.114217_bib25","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/31405","article-title":"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody","volume":"393","author":"Kwong","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114217_bib26","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/sim.1342","article-title":"Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal","volume":"22","author":"Gilbert","year":"2003","journal-title":"Stat. Med."},{"key":"10.1016\/j.ejmech.2022.114217_bib27","first-page":"481314","article-title":"HIV-1 genetic variability and clinical implications","author":"Santoro","year":"2013","journal-title":"ISRN Microbiol."},{"key":"10.1016\/j.ejmech.2022.114217_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1387-2656(07)13009-X","article-title":"Potentials of phenolic molecules of natural origin and their derivatives as anti-HIV agents","volume":"13","author":"Hassan Khan","year":"2007","journal-title":"Biotechnol. Annu. Rev."},{"key":"10.1016\/j.ejmech.2022.114217_bib29","doi-asserted-by":"crossref","first-page":"115431","DOI":"10.1016\/j.bmc.2020.115431","article-title":"Inhibition of HIV-1 RT activity by a new series of 3-(1,3,4-thiadiazol-2-yl)thiazolidin-4-one derivatives","volume":"28","author":"Buemi","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.addr.2016.01.017","article-title":"Nanomedicine in the development of anti-HIV microbicides","volume":"103","author":"das Neves","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2022.114217_bib31","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fchem.2020.00164","article-title":"In silico design of novel HIV-1 NNRTIs based on combined modeling studies of dihydrofuro[3,4-d]pyrimidines","volume":"8","author":"Chen","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV","volume":"33","author":"De Clercq","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2022.114217_bib33","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.coph.2010.04.011","article-title":"Antiretroviral drugs","volume":"10","author":"De Clercq","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114217_bib34","author":"HIVinfo"},{"key":"10.1016\/j.ejmech.2022.114217_bib35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/COH.0b013e328322402e","article-title":"HIV-1 Entry inhbitors: an overview","volume":"4","author":"Kuritzkes","year":"2009","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.ejmech.2022.114217_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.coviro.2012.12.002","article-title":"HIV-1 entry inhibitors: recent development and clinical use","volume":"3","author":"Henrich","year":"2013","journal-title":"Curr. opi. virol."},{"key":"10.1016\/j.ejmech.2022.114217_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-4690-1-9","article-title":"Early steps of retrovirus replicative cycle","volume":"1","author":"Nisole","year":"2004","journal-title":"Retrovirology"},{"key":"10.1016\/j.ejmech.2022.114217_bib38","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0960-894X(00)00321-8","article-title":"Synthesis and evaluation of quinoxalinones as HIV-1 reverse transcriptase inhibitors","volume":"10","author":"Patel","year":"2000","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114217_bib39","first-page":"411","article-title":"Nucleotide reverse transcriptase inhibitors: a thorough review, present status and future perspective as HIV therapeutics","volume":"15","author":"Holec","year":"2017","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.ejmech.2022.114217_bib40","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/17425255.2019.1673367","article-title":"Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment","volume":"15","author":"Wang","year":"2019","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.ejmech.2022.114217_bib41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.chom.2019.06.010","article-title":"The impact of HIV-1 drug escape on the global treatment landscape","volume":"26","author":"Collier","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ejmech.2022.114217_bib42","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1021\/bi0121858","article-title":"Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate","volume":"41","author":"Ray","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2022.114217_bib43","first-page":"1097","article-title":"Review of tenofovir-emtricitabine","volume":"3","author":"Masho","year":"2007","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.ejmech.2022.114217_bib44","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1128\/AAC.36.11.2423","article-title":"Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine","volume":"36","author":"Schinazi","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114217_bib45","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2165\/00003495-200565100-00008","article-title":"Emtricitabine: a review of its use in the management of HIV infection","volume":"65","author":"Frampton","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114217_bib46","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1086\/315711","article-title":"Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients","volume":"182","author":"Molina","year":"2000","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ejmech.2022.114217_bib47","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1097\/00002030-200411190-00007","article-title":"A\u00a0randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV","volume":"18","author":"Benson","year":"2004","journal-title":"Aids"},{"key":"10.1016\/j.ejmech.2022.114217_bib48","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.292.2.180","article-title":"Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial","volume":"292","author":"Saag","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2022.114217_bib49","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1086\/428091","article-title":"Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial","volume":"191","author":"Molina","year":"2005","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ejmech.2022.114217_bib50","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1046\/j.1365-2125.2000.00302.x","article-title":"The intracellular activation of lamivudine (3TC) and determination of 2\u2032-deoxycytidine-5\u2032-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells","volume":"50","author":"Kewn","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114217_bib51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0166-3542(97)00043-0","article-title":"Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in\u00a0vitro analyses","volume":"36","author":"Mulato","year":"1997","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2022.114217_bib52","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","article-title":"Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA","volume":"42","author":"Robbins","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114217_bib53","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2165\/00003495-200565030-00006","article-title":"Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection","volume":"65","author":"Lyseng-Williamson","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114217_bib54","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00006","article-title":"Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial","volume":"139","author":"Squires","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejmech.2022.114217_bib55","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2022.114217_bib56","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/135965350400900304","article-title":"Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach","volume":"9","author":"Negredo","year":"2004","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejmech.2022.114217_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","article-title":"The development of antiretroviral therapy and its impact on the HIV-1\/AIDS pandemic","volume":"85","author":"Broder","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2022.114217_bib58","first-page":"1","article-title":"Zidovudine (ZDV) and lamivudine (3TC) combination therapy for HIV infection-A review","volume":"2","author":"Navarrete","year":"1998","journal-title":"Braz. J. Infect. Dis.: an off. publi. Brazil. Soc. Infect. Dis."},{"key":"10.1016\/j.ejmech.2022.114217_bib59","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.37.5.1127","article-title":"U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication","volume":"37","author":"Dueweke","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114217_bib60","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.1073\/pnas.88.15.6863","article-title":"Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity","volume":"88","author":"Goldman","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2022.114217_bib61","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1128\/AAC.37.5.947","article-title":"A\u00a0nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors","volume":"37","author":"Goldman","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114217_bib62","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1126\/science.7532321","article-title":"Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors","volume":"267","author":"Spence","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114217_bib63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2009.09.008","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989\u20132009)","volume":"85","author":"de B\u00e9thune","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2022.114217_bib64","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/17425255.2019.1673367","article-title":"Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment","volume":"15","author":"Wang","year":"2019","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.ejmech.2022.114217_bib65","series-title":"PubChem Compound Summary for CID 5625","author":"Information","year":"2020"},{"key":"10.1016\/j.ejmech.2022.114217_bib66","series-title":"PubChem Compound Summary for CID 5625","year":"2020"},{"key":"10.1016\/j.ejmech.2022.114217_bib67","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1060028019869641","article-title":"Doravirine: a return of the NNRTI class?","volume":"54","author":"Blevins","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2022.114217_bib68","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s40262-019-00806-9","article-title":"Clinical pharmacodynamics, pharmacokinetics, and drug interaction profile of doravirine","volume":"58","author":"Boyle","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2022.114217_bib69","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/COH.0000000000000471","article-title":"Doravirine: a review","volume":"13","author":"Colombier","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.ejmech.2022.114217_bib70","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/COH.0000000000000474","article-title":"Rilpivirine long-acting for the prevention and treatment of HIV infection","volume":"13","author":"Ferretti","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.ejmech.2022.114217_bib71","series-title":"HIV Protease: Enzyme Function and Drug Resistance","author":"Gulnik","year":"2000"},{"key":"10.1016\/j.ejmech.2022.114217_bib72","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114217_bib73","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of second-line antiretroviral regimens for HIV therapy in Africa","volume":"371","author":"Paton","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114217_bib74","series-title":"Studies in Natural Products Chemistry","first-page":"197","article-title":"Interactions between natural health products and antiretroviral drugs","author":"Abad Mart\u00ednez","year":"2014"},{"key":"10.1016\/j.ejmech.2022.114217_bib75","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00126334-200301010-00004","article-title":"Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects","volume":"32","author":"Sanne","year":"2003","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ejmech.2022.114217_bib76","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1097\/00002030-200312050-00007","article-title":"Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results","volume":"17","author":"Murphy","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.ejmech.2022.114217_bib77","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00126334-200408150-00003","article-title":"Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV","volume":"36","author":"Squires","year":"2004","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ejmech.2022.114217_bib78","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"Niddk","year":"2012"},{"key":"10.1016\/j.ejmech.2022.114217_bib79","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2165\/00003495-200464180-00014","article-title":"Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection","volume":"64","author":"Chapman","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114217_bib80","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2147\/TCRM.S3109","article-title":"Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naive patients","volume":"4","author":"Flamholc","year":"2008","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.ejmech.2022.114217_bib81","series-title":"Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Content Repository Only!","first-page":"1622","article-title":"Antiretroviral therapy for human immunodeficiency virus infection","author":"Tsibris","year":"2015"},{"key":"10.1016\/j.ejmech.2022.114217_bib82","series-title":"Infectious Diseases","first-page":"1293","article-title":"Drugs for HIV infection","author":"Eckhardt","year":"2017"},{"key":"10.1016\/j.ejmech.2022.114217_bib83","series-title":"Chemical Product Design: toward a Perspective through Case Studies","first-page":"23","article-title":"The role of solubility modeling and crystallization in the design of active pharmaceutical ingredients","author":"Crafts","year":"2007"},{"key":"10.1016\/j.ejmech.2022.114217_bib84","series-title":"Applied Pharmacology, Content Repository Only!","first-page":"233","article-title":"Infectious diseases","author":"Bardal","year":"2011"},{"key":"10.1016\/j.ejmech.2022.114217_bib85","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/rmv.624","article-title":"The history of antiretrovirals: key discoveries over the past 25 years","volume":"19","author":"De Clercq","year":"2009","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.ejmech.2022.114217_bib86","series-title":"Introduction to Biological and Small Molecule Drug Research and Development","first-page":"355","article-title":"Design of the anti-HIV protease inhibitor darunavir","author":"Ghosh","year":"2013"},{"key":"10.1016\/j.ejmech.2022.114217_bib87","series-title":"Infectious Diseases","first-page":"918","article-title":"Antiviral therapy","author":"Bernardino","year":"2017"},{"key":"10.1016\/j.ejmech.2022.114217_bib88","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.2174\/1568026619666190119143239","article-title":"Structure based drug design: clinically relevant HIV-1 integrase inhibitors","volume":"18","author":"Kaur","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib89","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40121-014-0029-7","article-title":"Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV","volume":"3","author":"Dow","year":"2014","journal-title":"Infect. dis. ther."},{"key":"10.1016\/j.ejmech.2022.114217_bib90","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1128\/AAC.00842-09","article-title":"Pharmacokinetics and safety of S\/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers","volume":"54","author":"Min","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114217_bib91","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1128\/AAC.00625-13","article-title":"Characterization of binding of raltegravir to plasma proteins","volume":"57","author":"Barau","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114217_bib92","first-page":"413","article-title":"A.C.T.P.S.T. International Maternal Pediatric Adolescent, Pharmacokinetics, Safety, and 48-week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 through 18","volume":"58","author":"Nachman","year":"2014"},{"key":"10.1016\/j.ejmech.2022.114217_bib93","first-page":"587","article-title":"Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials, the Lancet","volume":"13","author":"Eron","year":"2013","journal-title":"Infect. dis."},{"key":"10.1016\/j.ejmech.2022.114217_bib94","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/jmr.2277","article-title":"Raltegravir flexibility and its impact on recognition by the HIV-1 IN targets","volume":"26","author":"Arora","year":"2013","journal-title":"J.\u00a0Mol. Recogn. : JMR (J. Mol. Recognit.)"},{"key":"10.1016\/j.ejmech.2022.114217_bib95","first-page":"1","article-title":"CCR5 inhibitors: emerging promising HIV therapeutic strategy","volume":"30","author":"Rao","year":"2009","journal-title":"Indian J. Sex. Transm. Dis."},{"key":"10.1016\/j.ejmech.2022.114217_bib96","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1007\/s00018-019-03255-6","article-title":"Dual CCR5\/CCR2 targeting: opportunities for the cure of complex disorders","volume":"76","author":"Fantuzzi","year":"2019","journal-title":"Cell. Mol. Life Sci. : CMLS"},{"key":"10.1016\/j.ejmech.2022.114217_bib97","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/v13050735","article-title":"HIV-1 entry and membrane fusion inhibitors","volume":"13","author":"Xiao","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2022.114217_bib98","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.2165\/00003495-200565130-00002","article-title":"Emerging drug targets for antiretroviral therapy","volume":"65","author":"Reeves","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114217_bib99","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1128\/AAC.00110-19","article-title":"Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection","volume":"63","author":"Beccari","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114217_bib100","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of Ibalizumab for multidrug-resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114217_bib101","series-title":"Boosted Protease Inhibitor (PI) Monotherapy for Treating HIV\/AIDS","first-page":"2017","author":"Jaoko","year":"2017"},{"key":"10.1016\/j.ejmech.2022.114217_bib102","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0b013e3181eb376b","article-title":"Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV","volume":"55","author":"German","year":"2010","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ejmech.2022.114217_bib103","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/clpt.2009.228","article-title":"Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity","volume":"87","author":"Mathias","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2022.114217_bib104","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40262-014-0167-9","article-title":"Pharmacokinetic enhancers in HIV therapeutics","volume":"53","author":"Larson","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2022.114217_bib105","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1128\/AAC.01089-12","article-title":"Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in\u00a0vitro","volume":"56","author":"Lepist","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114217_bib106","series-title":"StatPearls, StatPearls Publishing Copyright \u00a9 2020","article-title":"Tinea versicolor","author":"Karray","year":"2020"},{"key":"10.1016\/j.ejmech.2022.114217_bib107","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3389\/fmicb.2019.01461","article-title":"Antifungal activity and potential mechanism of N-butylphthalide alone and in combination with fluconazole against Candida albicans","volume":"10","author":"Gong","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejmech.2022.114217_bib108","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2018.07.016","article-title":"Natural product-derived compounds in HIV suppression, remission, and eradication strategies","volume":"158","author":"Andersen","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2022.114217_bib109","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1387-2656(07)13009-X","article-title":"Potentials of phenolic molecules of natural origin and their derivatives as anti-HIV agents","volume":"13","author":"Khan","year":"2007","journal-title":"Biotechnol. Annu. Rev."},{"key":"10.1016\/j.ejmech.2022.114217_bib110","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/molecules20010648","article-title":"Lectins with anti-HIV activity: a review","volume":"20","author":"Akkouh","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.114217_bib111","first-page":"2018","article-title":"Lectins as promising therapeutics for the prevention and treatment of HIV and other potential coinfections","author":"Mazalovska","year":"2018","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2022.114217_bib112","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1074\/jbc.M411122200","article-title":"Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp","volume":"280","author":"Mori","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib113","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.str.2010.05.016","article-title":"Monomerization of viral entry inhibitor griffithsin elucidates the relationship between multivalent binding to carbohydrates and anti-HIV activity","volume":"18","author":"Moulaei","year":"2010","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2022.114217_bib114","doi-asserted-by":"crossref","first-page":"6492346","DOI":"10.1155\/2021\/6492346","article-title":"Natural coumarins: exploring the pharmacological complexity and underlying molecular mechanisms","author":"Sharifi-Rad","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejmech.2022.114217_bib115","doi-asserted-by":"crossref","first-page":"103699","DOI":"10.1016\/j.bioorg.2020.103699","article-title":"Bioactive prenylated coumarins as potential anti-inflammatory and anti-HIV agents from Clausena lenis","volume":"97","author":"Liu","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib116","doi-asserted-by":"crossref","first-page":"103699","DOI":"10.1016\/j.bioorg.2020.103699","article-title":"Bioactive prenylated coumarins as potential anti-inflammatory and anti-HIV agents from Clausena lenis","volume":"97","author":"Liu","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib117","doi-asserted-by":"crossref","first-page":"11942","DOI":"10.1021\/acs.jafc.9b04326","article-title":"Prenylated coumarins from the fruits of Manilkara zapota with potential anti-inflammatory effects and anti-HIV activities","volume":"67","author":"Liu","year":"2019","journal-title":"J.\u00a0Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib118","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1021\/acs.jafc.9b06417","article-title":"Prenylated chromones from the fruits of artocarpus heterophyllus and their potential anti-HIV-1 activities","volume":"68","author":"Fu","year":"2020","journal-title":"J.\u00a0Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib119","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3390\/molecules24091842","article-title":"A\u00a0review on daphnane-type diterpenoids and their bioactive studies","volume":"24","author":"Jin","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.114217_bib120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1021\/acs.orglett.9b03539","article-title":"Anti-HIV gnidimacrin related macrocyclic daphnane orthoesters from Daphne odora","volume":"22","author":"Otsuki","year":"2020","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2022.114217_bib121","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1021\/acs.jnatprod.9b00993","article-title":"Rapid recognition and targeted isolation of anti-HIV daphnane diterpenes from Daphne genkwa guided by UPLC-MS(n)","volume":"83","author":"Zhao","year":"2020","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2022.114217_bib122","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1021\/acs.jnatprod.9b00088","article-title":"Potent anti-HIV ingenane diterpenoids from Euphorbia ebracteolata","volume":"82","author":"Huang","year":"2019","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2022.114217_bib123","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1021\/acs.jnatprod.9b00088","article-title":"Potent anti-HIV ingenane diterpenoids from Euphorbia ebracteolata","volume":"82","author":"Huang","year":"2019","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2022.114217_bib124","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1021\/acs.jnatprod.8b00243","article-title":"3,4- seco-norclerodane diterpenoids from the roots of Polyalthia laui","volume":"82","author":"Yu","year":"2019","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2022.114217_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2018.10.013","article-title":"Bioactive monoterpene indole alkaloids from Nauclea officinalis","volume":"83","author":"Liu","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib126","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejmech.2019.01.020","article-title":"Discovery and synthesis of novel beesioside I derivatives with potent anti-HIV activity","volume":"166","author":"Wu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib127","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.phytol.2019.10.007","article-title":"Cytotoxic and anti-HIV-1 activities of triterpenoids and flavonoids isolated from leaves and twigs of Gardenia sessiliflora","volume":"35","author":"Thanasansurapong","year":"2020","journal-title":"Phytochem. Lett."},{"key":"10.1016\/j.ejmech.2022.114217_bib128","article-title":"A\u00a0new ellagic acid from the leaves and twigs of irvingia malayana","volume":"14","author":"Jaipetch","year":"2019","journal-title":"Nat. Prod. Commun."},{"key":"10.1016\/j.ejmech.2022.114217_bib129","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bjp.2019.04.001","article-title":"Chemical characterization, antioxidant and anti-HIV activities of a Brazilian propolis from Cear\u00e1 state","volume":"29","author":"Silva","year":"2019","journal-title":"Rev. Brasil. de Farmacogn."},{"key":"10.1016\/j.ejmech.2022.114217_bib130","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.sajb.2019.04.023","article-title":"Anti-HIV-1 activity of quinic acid isolated from Helichrysum mimetes using NMR-based metabolomics and computational analysis","volume":"126","author":"Yazdi","year":"2019","journal-title":"South Afr. J. Bot."},{"key":"10.1016\/j.ejmech.2022.114217_bib131","doi-asserted-by":"crossref","first-page":"104388","DOI":"10.1016\/j.fitote.2019.104388","article-title":"Anti-HIV-1 activities of constituents from the rhizomes of Boesenbergia thorelii","volume":"139","author":"Thongphichai","year":"2019","journal-title":"Fitoterapia"},{"key":"10.1016\/j.ejmech.2022.114217_bib132","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jpba.2019.05.065","article-title":"Biological activity and stability analyses of knipholone anthrone, a phenyl anthraquinone derivative isolated from Kniphofia foliosa Hochst","volume":"174","author":"Feilcke","year":"2019","journal-title":"J.\u00a0Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2022.114217_bib133","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.3390\/molecules24173202","article-title":"Cordidepsine is A Potential new anti-HIV depsidone from Cordia millenii","volume":"24","author":"Dongmo Zeukang","year":"2019","journal-title":"Baker, Mol.(Basel, Switzerland)"},{"key":"10.1016\/j.ejmech.2022.114217_bib134","first-page":"270418","article-title":"Biological significance of urolithins, the gut microbial ellagic acid-derived metabolites: the evidence so far","author":"Esp\u00edn","year":"2013","journal-title":"Evid. base Compl. Alternative Med."},{"key":"10.1016\/j.ejmech.2022.114217_bib135","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.sajb.2018.08.010","article-title":"Biological activity of plant extracts and isolated compounds from Alchornea laxiflora: anti-HIV, antibacterial and cytotoxicity evaluation","volume":"122","author":"Siwe-Noundou","year":"2019","journal-title":"South Afr. J. Bot."},{"key":"10.1016\/j.ejmech.2022.114217_bib136","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/odi.12835","article-title":"Ellagic acid inhibits HIV-1 infection in\u00a0vitro: potential role as a novel microbicide","volume":"24","author":"Promsong","year":"2018","journal-title":"Oral Dis."},{"key":"10.1016\/j.ejmech.2022.114217_bib137","doi-asserted-by":"crossref","first-page":"146","DOI":"10.18311\/jnr\/2019\/23766","article-title":"In\u00a0vitro evaluation of crude extracts and isolated compounds from Goniothalamus rongklanus and Goniothalamus latestigma for bioactive properties","volume":"19","author":"Funnimid","year":"2019","journal-title":"J.\u00a0Nat. Remedies"},{"key":"10.1016\/j.ejmech.2022.114217_bib138","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12906-019-2766-3","article-title":"Anti-HIV-1 protease activity of the crude extracts and isolated compounds from Auricularia polytricha","volume":"19","author":"Sillapachaiyaporn","year":"2019","journal-title":"BMC Compl. Alternative Med."},{"key":"10.1016\/j.ejmech.2022.114217_bib139","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.sajb.2018.10.008","article-title":"In\u00a0vitro antimalarial, antitrypanosomal and HIV-1 integrase inhibitory activities of two Cameroonian medicinal plants: Antrocaryon klaineanum (Anacardiaceae) and Diospyros conocarpa (Ebenaceae)","volume":"122","author":"Fouokeng","year":"2019","journal-title":"South Afr. J. Bot."},{"key":"10.1016\/j.ejmech.2022.114217_bib140","volume":"17","author":"Izumida","year":"2019"},{"key":"10.1016\/j.ejmech.2022.114217_bib141","doi-asserted-by":"crossref","first-page":"112931","DOI":"10.1016\/j.jep.2020.112931","article-title":"Development of a pseudovirus assay and evaluation to screen natural products for inhibition of HIV-1 subtype C reverse transcriptase","volume":"258","author":"Mavhandu","year":"2020","journal-title":"J.\u00a0Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2022.114217_bib142","series-title":"Studies in Natural Products Chemistry","first-page":"225","article-title":"Natural products from plants with prospective anti-HIV activity and relevant mechanisms of action","author":"Mandal","year":"2020"},{"key":"10.1016\/j.ejmech.2022.114217_bib143","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35073673","article-title":"HIV chemotherapy","volume":"410","author":"Richman","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114217_bib144","first-page":"113567","article-title":"A\u00a0review of the phytochemistry and pharmacology of Kadsura heteroclita, an important plant in Tujia ethnomedicine","author":"Wang","year":"2020","journal-title":"J.\u00a0Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2022.114217_bib145","doi-asserted-by":"crossref","first-page":"9648056","DOI":"10.1155\/2020\/9648056","article-title":"Inhibition of HIV-1 protease by Carpobrotus edulis (L.)","author":"Omoruyi","year":"2020","journal-title":"Evid. Based Compl. Alternat. Med."},{"key":"10.1016\/j.ejmech.2022.114217_bib146","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12906-020-2816-x","article-title":"In\u00a0vitro anti-HIV activity of some Indian medicinal plant extracts","volume":"20","author":"Palshetkar","year":"2020","journal-title":"BMC Compl. Med. Ther."},{"key":"10.1016\/j.ejmech.2022.114217_bib147","first-page":"12","article-title":"Potent and selective activity against human immunodeficiency virus 1 (HIV-1) of Thymelaea hirsuta extracts","author":"Sanna","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2022.114217_bib148","doi-asserted-by":"crossref","first-page":"e1846","DOI":"10.1038\/cddis.2015.204","article-title":"Syncytial apoptosis signaling network induced by the HIV-1 envelope glycoprotein complex: an overview","volume":"6","author":"Nardacci","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2022.114217_bib149","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1128\/AAC.48.10.3858-3870.2004","article-title":"Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection","volume":"48","author":"Balzarini","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114217_bib150","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.fitote.2012.10.017","article-title":"Nerium oleander derived cardiac glycoside oleandrin is a novel inhibitor of HIV infectivity","volume":"84","author":"Singh","year":"2013","journal-title":"Fitoterapia"},{"key":"10.1016\/j.ejmech.2022.114217_bib151","first-page":"1","article-title":"Aqueous extracts of Thai medicinal plants possess anti-HIV-1 activity","author":"Panvilai","year":"2020","journal-title":"J.\u00a0Herbs, Spices, Med. Plants"},{"key":"10.1016\/j.ejmech.2022.114217_bib152","doi-asserted-by":"crossref","first-page":"127773","DOI":"10.1016\/j.foodchem.2020.127773","article-title":"Phytochemical and pharmacological review of Cinnamomum verum J. Presl-a versatile spice used in food and nutrition","volume":"338","author":"Singh","year":"2021","journal-title":"Food Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib153","first-page":"13777","article-title":"Isolation, characterization and purification of bio-active compounds from andrographispaniculata and cinnamon verum for anti-hiv activity","volume":"3","author":"Gopinath","year":"2014","journal-title":"IJIRSET"},{"key":"10.1016\/j.ejmech.2022.114217_bib154","doi-asserted-by":"crossref","first-page":"113163","DOI":"10.1016\/j.jep.2020.113163","article-title":"Ethanolic extract of Artemisia campestris subsp. glutinosa (Besser) Batt. inhibits HIV\u20131 replication in\u00a0vitro through the activity of terpenes and flavonoids on viral entry and NF\u2013\u03baB pathway","volume":"263","author":"Apaza Ticona","year":"2020","journal-title":"J.\u00a0Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2022.114217_bib155","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/med.21708","article-title":"Recent advances in natural anti-HIV triterpenoids and analogs","volume":"40","author":"Wu","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2022.114217_bib156","series-title":"Ziziphus Jujuba Mill., a Plant Used as Medicinal Food: a Review of its Phytochemistry, Pharmacology, Quality Control and Future Research","author":"Liu","year":"2020"},{"key":"10.1016\/j.ejmech.2022.114217_bib157","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1021\/np50104a008","article-title":"Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids","volume":"57","author":"Fujioka","year":"1994","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2022.114217_bib158","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.sajb.2020.10.018","article-title":"Nutritional and bioactive potential of seagrasses: a review","volume":"137","author":"Kim","year":"2021","journal-title":"South Afr. J. Bot."},{"key":"10.1016\/j.ejmech.2022.114217_bib159","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1016\/S0968-0896(02)00241-9","article-title":"New marine-derived inhibitors of HIV cDNA integrase","volume":"10","author":"Rowley","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib160","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.26452\/ijrps.v11i4.3291","article-title":"Plant-derived alkaloids as anti-viral agents","volume":"11","author":"Nagasathiya","year":"2020","journal-title":"Int. J. Res. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2022.114217_bib161","doi-asserted-by":"crossref","first-page":"103782","DOI":"10.1016\/j.bioorg.2020.103782","article-title":"Design, synthesis and biological evaluation of novel 5-((substituted quinolin-3-yl\/1-naphthyl) methylene)-3-substituted imidazolidin-2,4-dione as HIV-1 fusion inhibitors","volume":"99","author":"Ibrahim","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib162","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1016\/j.bmcl.2011.08.081","article-title":"Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans\/pyrroles as HIV-1 fusion inhibitors targeting gp41","volume":"21","author":"Jiang","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114217_bib163","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.apsb.2019.08.009","article-title":"Synthesis and biological evaluation of a series of 2-(((5-akly\/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones as potential HIV-1 inhibitors","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2022.114217_bib164","doi-asserted-by":"crossref","first-page":"103825","DOI":"10.1016\/j.bioorg.2020.103825","article-title":"Privileged scaffold inspired design of novel oxime-biphenyl-DAPYs in treatment of HIV-1","volume":"99","author":"Yang","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib165","doi-asserted-by":"crossref","first-page":"111987","DOI":"10.1016\/j.ejmech.2019.111987","article-title":"Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme","volume":"188","author":"Fabian","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib166","doi-asserted-by":"crossref","first-page":"112255","DOI":"10.1016\/j.ejmech.2020.112255","article-title":"Design, synthesis, in\u00a0vitro and in silico studies of novel 4-oxoquinoline ribonucleoside derivatives as HIV-1 reverse transcriptase inhibitors","volume":"194","author":"Forezi","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib167","doi-asserted-by":"crossref","first-page":"112111","DOI":"10.1016\/j.ejmech.2020.112111","article-title":"Design, synthesis and biological evaluation of novel 2-(5-aryl-1H-imidazole-1-yl) derivatives as potential inhibitors of the HIV-1 Vpu and host BST-2 protein interaction","volume":"190","author":"Rashamuse","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib168","doi-asserted-by":"crossref","first-page":"112085","DOI":"10.1016\/j.ejmech.2020.112085","article-title":"Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities","volume":"190","author":"Sun","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib169","doi-asserted-by":"crossref","first-page":"111864","DOI":"10.1016\/j.ejmech.2019.111864","article-title":"Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: design, synthesis and biological activities","volume":"186","author":"Xiao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib170","doi-asserted-by":"crossref","first-page":"111900","DOI":"10.1016\/j.ejmech.2019.111900","article-title":"Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase","volume":"186","author":"Zhu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib171","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/s41598-020-57843-9","article-title":"Potent inhibition of HIV replication in primary human cells by novel synthetic polyketides inspired by Aureothin","volume":"10","author":"Herrmann","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2022.114217_bib172","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1021\/acs.jmedchem.7b00332","article-title":"Structure-based optimization of thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with improved potency against resistance-associated variants","volume":"60","author":"Kang","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib173","doi-asserted-by":"crossref","first-page":"151598","DOI":"10.1016\/j.tetlet.2020.151598","article-title":"Synthesis, characterization and anti-HIV activity of polycarboxylic [60]fullerene derivatives obtained in the reaction of C60Cl6 with a hydroquinone ether","volume":"61","author":"Voronov","year":"2020","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2022.114217_bib174","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2019.04.010","article-title":"Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV","volume":"167","author":"Kudalkar","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2022.114217_bib175","doi-asserted-by":"crossref","first-page":"104648","DOI":"10.1016\/j.antiviral.2019.104648","article-title":"A\u00a0novel isothiocyanate derivative inhibits HIV-1 gene expression and replication by modulating the nuclear matrix associated protein SMAR1","volume":"173","author":"Trivedi","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2022.114217_bib176","doi-asserted-by":"crossref","first-page":"103521","DOI":"10.1016\/j.bioorg.2019.103521","article-title":"Synthesis, molecular docking and biological evaluation of 2-(thiophen-2-yl)-1H-indoles as potent HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"95","author":"El-Hussieny","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib177","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/cbdd.13455","article-title":"Design, synthesis, and biologic evaluation of novel galloyl derivatives as HIV-1 RNase H inhibitors","volume":"93","author":"Gao","year":"2019","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2022.114217_bib178","doi-asserted-by":"crossref","first-page":"111617","DOI":"10.1016\/j.ejmech.2019.111617","article-title":"Chromenone derivatives as a versatile scaffold with dual mode of inhibition of HIV-1 reverse transcriptase-associated Ribonuclease H function and integrase activity","volume":"182","author":"Esposito","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib179","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejmech.2019.05.011","article-title":"Synthesis and biological evaluation of dihydroquinazoline-2-amines as potent non-nucleoside reverse transcriptase inhibitors of wild-type and mutant HIV-1 strains","volume":"176","author":"Jin","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib180","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejmech.2019.04.051","article-title":"Dual activity of amphiphilic Zn(II) nitroporphyrin derivatives as HIV-1 entry inhibitors and in cancer photodynamic therapy","volume":"174","author":"Sengupta","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib181","doi-asserted-by":"crossref","first-page":"111619","DOI":"10.1016\/j.ejmech.2019.111619","article-title":"Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing","volume":"182","author":"Zhao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib182","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3389\/fchem.2019.00574","article-title":"Identification of novel 3-Hydroxy-pyran-4-One derivatives as potent HIV-1 integrase inhibitors using in silico structure-based combinatorial library design approach","volume":"7","author":"Sirous","year":"2019","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib183","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20205209","article-title":"New phosphorus analogs of bevirimat: synthesis, evaluation of anti-HIV-1 activity and molecular docking study","volume":"20","author":"Chrobak","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2022.114217_bib184","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.3390\/molecules24213821","article-title":"Novel thiazolidin-4-ones as potential non-nucleoside inhibitors of HIV-1 reverse transcriptase","volume":"24","author":"Petrou","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.114217_bib185","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/15257770.2018.1541466","article-title":"Synthesis and in\u00a0vitro biological evaluation of novel thymidine analogs containing 1H-1,2,3-Triazolyl, 1H-tetrazolyl, and 2H-tetrazolyl fragments","volume":"38","author":"Popova","year":"2019","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.ejmech.2022.114217_bib186","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4103\/1735-5362.253363","article-title":"Design, synthesis and evaluation of cytotoxic, antimicrobial, and anti-HIV-1 activities of new 1,2,3,4-tetrahydropyrimidine derivatives","volume":"14","author":"Razzaghi-Asl","year":"2019","journal-title":"Res. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2022.114217_bib187","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.201800532","article-title":"Synthesis and anti-HIV activity of guanine modified fluorinated acyclic nucleoside phosphonate derivatives","volume":"16","author":"Luo","year":"2019","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2022.114217_bib188","doi-asserted-by":"crossref","DOI":"10.1177\/2040206619826265","article-title":"Synthesis and anti-human immunodeficiency virus activity of substituted (o,o-difluorophenyl)-linked-pyrimidines as potent non-nucleoside reverse transcriptase inhibitors","volume":"27","author":"\u010cechov\u00e1","year":"2019","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.ejmech.2022.114217_bib189","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.bmc.2018.12.039","article-title":"Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs","volume":"27","author":"Wang","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib190","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.bmcl.2018.12.040","article-title":"Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands","volume":"29","author":"Zhu","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114217_bib191","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1021\/acs.jmedchem.8b01238","article-title":"Effect of \u03b1-methoxy substitution on the anti-HIV activity of dihydropyrimidin-4(3 H)-ones","volume":"62","author":"Nawrozkij","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib192","doi-asserted-by":"crossref","first-page":"28961","DOI":"10.1039\/C9RA05869A","article-title":"Discovery of novel 1,4-disubstituted 1,2,3-triazole phenylalanine derivatives as HIV-1 capsid inhibitors","volume":"9","author":"Jiang","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2022.114217_bib193","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.14233\/ajchem.2019.22045","article-title":"Synthesis and biological evaluation of novel diketoquinoline analogues as HIV-1 integrase inhibitor","volume":"31","author":"Deo","year":"2019","journal-title":"Asian J. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib194","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3390\/molecules24091718","article-title":"Pyrimidine 2,4-diones in the design of new HIV RT inhibitors","volume":"24","author":"Romeo","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.114217_bib195","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1039\/C8MD00328A","article-title":"Evaluation of novel N\u2032-(3-hydroxybenzoyl)-2-oxo-2H-chromene-3-carbohydrazide derivatives as potential HIV-1 integrase inhibitors","volume":"10","author":"Jesumoroti","year":"2019","journal-title":"Med. Chem. Comm."},{"key":"10.1016\/j.ejmech.2022.114217_bib196","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1248\/bpb.b18-00705","article-title":"Synthesis and biological evaluation of 3,9-dioxatetraasteranes as C(2)-symmetric HIV-1 protease inhibitors and docking study","volume":"42","author":"Li","year":"2019","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2022.114217_bib197","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3389\/fphar.2019.00859","article-title":"N-substituted pyrrole derivative 12m inhibits HIV-1 entry by targeting Gp41 of HIV-1 envelope glycoprotein","volume":"10","author":"Qiu","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114217_bib198","first-page":"11","article-title":"A\u00a0novel CXCR4 targeting protein SDF-1\/54 as an HIV-1 entry inhibitor","author":"Tan","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2022.114217_bib199","series-title":"Design, Conformation, and Crystallography of 2-Naphthyl Phenyl Ethers as Potent Anti-HIV Agents","first-page":"1156","author":"Lee","year":"2016"},{"key":"10.1016\/j.ejmech.2022.114217_bib200","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cmdc.201800804","article-title":"Synthesis and antiviral evaluation of 3'-Fluoro-4'-modified-5'-norcarbocyclic nucleoside phosphonates","volume":"14","author":"Geant","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114217_bib201","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acs.jmedchem.5b00497","article-title":"Anti-HIV drug discovery and development: current innovations and future trends","volume":"59","author":"Zhan","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib202","doi-asserted-by":"crossref","first-page":"42","DOI":"10.31925\/farmacia.2020.1.7","article-title":"Liver function IN a cohort OF young HIV-HBV CO-infected patients ON long-term combined antiretroviral therapy","volume":"68","author":"Rosca","year":"2020","journal-title":"FARMACIA"},{"key":"10.1016\/j.ejmech.2022.114217_bib203","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/j.bmc.2016.07.039","article-title":"Computer-aided discovery of anti-HIV agents","volume":"24","author":"Jorgensen","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114217_bib204","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/13543776.2018.1438410","article-title":"Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014-2017)","volume":"28","author":"Zuo","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2022.114217_bib205","series-title":"A\u00a0Pharmacological Perspective on Plant-Derived Bioactive Molecules for Epilepsy","author":"Sharifi-Rad","year":"2021"},{"key":"10.1016\/j.ejmech.2022.114217_bib206","doi-asserted-by":"crossref","first-page":"2910411","DOI":"10.1155\/2022\/2910411","article-title":"Nutraceutical profiling, bioactive composition, and biological applications of Lepidium sativum L","author":"Painuli","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejmech.2022.114217_bib207","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12935-021-02025-4","article-title":"Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment","volume":"21","author":"Sharifi-Rad","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2022.114217_bib208","doi-asserted-by":"crossref","first-page":"3687700","DOI":"10.1155\/2021\/3687700","article-title":"Paclitaxel: application in modern oncology and nanomedicine-based cancer therapy","author":"Sharifi-Rad","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejmech.2022.114217_bib209","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/biom10010130","article-title":"Avocado\u2013soybean unsaponifiables: a panoply of potentialities to Be exploited","volume":"10","author":"Salehi","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2022.114217_bib210","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/ptr.6884","article-title":"Ficus plants: state of the art from a phytochemical, pharmacological, and toxicological perspective","volume":"35","author":"Salehi","year":"2021","journal-title":"Phytother Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422001192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422001192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:01:37Z","timestamp":1777528897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422001192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":209,"alternative-id":["S0223523422001192"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114217","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural products and synthetic analogues against HIV: A perspective to develop new potential anti-HIV drugs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114217"}}